Factual and Procedural Background
The claimants, two research scientists employed by Company A, were involved in synthesising a compound called P53 that led to a patented radioactive imaging agent marketed under the trademark Myoview. They sought compensation under Section 40 of the Patents Act 1977, claiming a share of the benefit derived by their employer from the patents. Company A had been acquired by Company B, which continued the relevant healthcare division. The case involved two patent families with priority dates in 1987 and 1988, expiring around 2008-2009, with protection in the United States extending to 2010. Three Company A employees are named inventors, with two claimants participating in the claim. External academics named as inventors could not claim compensation under section 40 as their employers did not hold the patents.
The litigation centers on the interpretation and application of the statutory scheme for inventor compensation, particularly concerning the entitlement to compensation, the meaning of "outstanding benefit," and the calculation of a fair share of benefits derived from the patents. The court considered detailed technical and commercial evidence regarding the invention, development, and commercial success of Myoview, including the role of patent protection in corporate deals and market exclusivity.
Legal Issues Presented
- Whether the claimants made inventions belonging to their employer for which patents were granted.
- Whether the patents were of outstanding benefit to the employer within the meaning of Section 40(1) of the Patents Act 1977.
- Whether, by reason of those facts, it is just to award the claimants compensation.
- How to assess the value of the benefit derived from the patents and determine a fair share of that benefit for the claimants under Section 41.
- Whether regulatory data exclusivity constitutes "other protection" under the expanded definition of "patent" in Section 43(4).
Arguments of the Parties
Appellants' Arguments
- The claimants asserted entitlement to compensation as actual inventors under Section 40(1), emphasizing that the patents had been of outstanding benefit to their employer.
- They argued that the benefit derived from the patents should be valued ex post, considering actual profits and corporate advantages secured, including significant sales and strategic deals.
- They contended that regulatory data exclusivity should be considered alongside patents as a form of protection enhancing the benefit.
- They proposed a fair share of the benefit based on industry licensing rates adjusted for relevant factors.
Employer's Arguments
- The employer contended that the patents were only one of multiple causes of the product's success, and that the benefit attributable to the patents should be apportioned accordingly.
- It was argued that regulatory data exclusivity is not "other protection" granting monopoly rights and thus should not be included in the benefit calculation.
- The employer submitted that compensation under Section 40 is meant to remedy unfair loss due to inequality of bargaining power and that the claimants had received adequate remuneration and benefits.
- They suggested that any award should be nominal or limited to a bonus relative to the claimants' salaries, highlighting the collective and corporate nature of the research effort.
- The employer pointed to the timing of the claimants' application and absence of prior complaints as factors against justifying compensation.
Table of Precedents Cited
| Precedent |
Rule or Principle Cited For |
Application by the Court |
| Yeda Research v Rhone-Poulenc Rorer [2007] UKHL 43; [2008] RPC 1 |
Definition of "actual deviser" of an invention as the natural person who came up with the inventive concept. |
Confirmed that compensation under Section 40 is available only to actual inventors, not to those contributing non-patentable elements. |
| University of Southampton's Application [2005] RPC 11 |
Clarified that contribution must be to the formulation of the inventive concept. |
Supported the court's interpretation of "actual deviser" in the context of inventor compensation. |
| Henry Brothers (Magherafelt) Limited v Ministry of Defence [1997] RPC 693; [1999] RPC 442 |
Distinction between patentable inventive contribution and non-patentable contributions. |
Reinforced the requirement for actual inventive contribution for compensation eligibility. |
| LIFFE Administration & Management v Pinkava [2007] RPC 30 |
Interpretation of "in the course of normal duties" as broader than day-to-day work. |
Applied to determine ownership of inventions and entitlement to compensation under Section 39 and 40. |
| Memco-Med Ltd's Patent [1992] RPC 403 |
Interpretation of "outstanding benefit" as more than substantial or good; qualitative assessment. |
Guided the court's assessment of whether the patents were of outstanding benefit to the employer. |
| GEC Avionics Limited's Patent (Ellis' Application) [1992] RPC 107 |
Rationale for using "outstanding" to qualify benefit, emphasizing benefit beyond normal expectations. |
Supported the qualitative approach to outstanding benefit and consideration of employer's undertaking size. |
| British Steel PLC's Patent (Monks' Application) [1992] RPC 117 |
Characterization of "outstanding" as a comparative and superlative term. |
Used to clarify the level of benefit required for compensation under Section 40. |
| Gerber v Lectra [1995] RPC 383 |
Discussion on estimating damages and the "but for" test in patent infringement. |
Informed the court's approach to assessing benefit derived from the patent by comparison with a non-patented scenario. |
| Performing Right Society Ltd v British Entertainment and Dancing Association Ltd [1993] EMLR 325 |
Consideration of causal relationship in assessing royalties. |
Discussed but distinguished as not directly applicable to patent compensation causation. |
Court's Reasoning and Analysis
The court began by establishing that the claimants were actual inventors named on the patents and that the inventions belonged to their employer under Section 39. It emphasized that Section 40 compensation is available only to actual inventors, not to those who merely contributed without inventive input.
The court analyzed the meaning of "outstanding benefit," adopting a qualitative standard requiring benefit to be more than substantial or good, but not necessarily superlative. It rejected the employer's argument that compensation is only to remedy loss, instead interpreting compensation as addressing the disparity between benefits to employer and employee.
Regarding the "but for" test, the court acknowledged its utility as an exclusionary tool but recognized that multiple causes may contribute to the benefit derived from a patent. The key question is whether the patent was a cause of the benefit, with apportionment necessary where multiple causes exist.
The court considered whether regulatory data exclusivity (RDE) constitutes "other protection" under the expanded definition of "patent" and concluded that RDE is not monopoly protection of the invention and thus excluded from the patent benefit calculation.
On the question of whether it is just to award compensation, the court rejected arguments that lack of prior complaint or timing of claim preclude an award. It held that the statutory scheme contemplates just awards based on outstanding benefit and fairness, not limited by loss or remuneration considerations alone.
In valuing the benefit, the court rejected the employer's ex ante relief-from-royalty approach, favoring an ex post valuation based on actual profits and market developments. It conservatively estimated the patent benefit at £50 million, noting this as a rock bottom figure.
In assessing a fair share under Section 41, the court considered factors including the nature of the claimants' duties, their remuneration, effort and skill, contributions of others, and the employer's role. It acknowledged the claimants' significant inventive input and the employer's substantial support and risk assumption.
The court rejected the employer's proposal for nominal or salary-based awards, instead determining a fair share of 3% of the benefit, split as 2% to the senior claimant and 1% to the junior claimant, reflecting their relative contributions and industry comparators.
Holding and Implications
The court held that the patents were of outstanding benefit to the employer and that it is just to award compensation to the claimants.
The court awarded compensation amounting to £1 million to the senior claimant and £500,000 to the junior claimant, representing a fair share of the benefit derived from the patents. This award is a once-and-for-all sum reflecting the totality of the benefit and the claimants' contributions.
The decision directly affects the parties by providing substantial compensation to the claimants but does not establish new legal precedent beyond clarifying the interpretation of Section 40 and 41 in this context.